Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Everest Medicines : Wins License to Kidney Disease Treatment; Shares Rise 4%

09/17/2021 | 01:57am EST


ę MT Newswires 2021
All news about EVEREST MEDICINES LIMITED
01/13Everest Medicines Unit Secures Global License to Products, Tech for Coronavirus Treatme..
MT
01/13Everest Medicines Limited Enters into A Global Licensing Agreement to Develop, Manufact..
CI
01/11Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combi..
AQ
01/10Everest Medicines Will Participate in Clinical Trial with Gilead and Msd to Evaluate Tr..
CI
01/03Everest Medicines Limited Announces Taiwan FDA Has Accepts New Drug Application for Sac..
CI
2021Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vacc..
CI
2021Everest Medicines Limited Announces Acceptance of New Drug Application for Sacituzumab ..
CI
2021Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Stra..
CI
2021Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China..
PR
2021Everest Medicines' Phase 2b Trial in China of Breast Cancer Drug Meets Study Endpoint; ..
MT
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Financials
Sales 2021 1,91 M 0,30 M 0,30 M
Net income 2021 -1 046 M -165 M -165 M
Net cash 2021 3 029 M 477 M 477 M
P/E ratio 2021 -10,1x
Yield 2021 -
Capitalization 10 726 M 1 377 M 1 691 M
EV / Sales 2021 4 023x
EV / Sales 2022 11,6x
Nbr of Employees 227
Free-Float -
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 36,15 CNY
Average target price 80,82 CNY
Spread / Average Target 124%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Chairman
Jennifer Yang Chief Scientific Officer
Xiaofan Zhang Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED3.88%1 500
CSL LIMITED-5.85%94 127
WUXI BIOLOGICS (CAYMAN) INC.-6.16%48 241
SAMSUNG BIOLOGICS CO.,LTD.-9.63%44 698
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-2.55%34 345